Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$130.01M-237%-$38.63M
$8.34M-0.2%$8.36M+0.3%$8.33M-0.1%$8.34M+0.8%$8.27M+1.9%
$19.52M+3.5%$18.87M-0.8%$19.03M+0.4%$18.94M+2.1%$18.55M+2.3%
-$14.68M+35.6%-$22.8M-115%$149.14M+438%$27.72M-20.1%$34.67M-17.4%
$4.98M+6.0%$4.7M+14.2%$4.12M+6.5%$3.86M-7.8%$4.19M+5.1%
$358.67M+1,082%$30.35M+2,173%$1.34M+33.2%$1M-99.0%$98.66M-0.2%
-$19.66M+28.5%-$27.5M-119%$145.02M+508%$23.85M-21.7%$30.48M-19.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Monte Rosa Therapeutics, Inc. generate?
Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
What is Monte Rosa Therapeutics, Inc.'s free cash flow?
After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.